Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended.
This pharma reimbursement strategy of Türkiye aims to prevent citizens from buying overly expensive medicines, to pay the most advantageous global prices.
Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval of fruquintinib a selective inhibitor of vascular endothelial growth factor receptors VEGFR 1 2 and 3 for the treatment of adult patients with previously treated metastatic colorectal cancer mCRC.